Table 1 Baseline characteristics of enrolled patients with COVID-19
UC-MSCs treatment group (n = 9) | Control group (n = 9) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Patient number | T1 | T2 | T3 | T4 | T5 | T6 | T7 | T8 | T9 | C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | C9 |
Age (years) | 45 | 44 | 45 | 39 | 64 | 40 | 36 | 59 | 34 | 54 | 44 | 53 | 67 | 37 | 33 | 48 | 60 | 50 |
Sex | M | M | F | F | M | M | M | M | M | F | F | F | M | M | M | M | F | F |
Severity of disease | Mod | Mod | Mod | Mod | Mod | Sev | Sev | Sev | Sev | Mod | Mod | Mod | Mod | Mod | Sev | Sev | Sev | Sev |
Co-existing presentation diseases | No | HTN | No | No | No | Diabetes | No | HTN | Fatty liver disease | No | No | No | No | HTN | No | No | Asthma | No |
Interval between symptom onset and admission (days) | 3 | 6 | 6 | 7 | 15 | 3 | 3 | 7 | 10 | 4 | 8 | 8 | 6 | 5 | 7 | 6 | 6 | 11 |
Viral RNA at enrollment | + | + | + | + | − | + | + | + | − | − | + | + | + | + | + | + | + | + |
Antivirals treatment | LPV/r | LPV/r | LPV/r | LPV/r | LPV/r | LPV/r | LPV/r | LPV/r | No | LPV/r | LPV/r | LPV/r | No | LPV/r | LPV/r | LPV/r | LPV/r | LPV/r |
Steroids treatment | GC | GC | GC | GC | GC | GC | GC | GC | GC | No | No | No | GC | GC | GC | GC | GC | GC |
